PROTAC as a novel anti-cancer strategy by targeting aging-related signaling.

Yunhua Peng, Donghua Liu, Daoyuan Huang, Hiroyuki Inuzuka, Jing Liu

Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an 710049, China. · pubmed

Paper

Abstract

Aging and cancer share common cellular hallmarks, including cellular senescence, genomic instability, and abnormal cell death and proliferation, highlighting potential areas for therapeutic interventions. Recent advancements in targeted protein degradation technologies, notably Proteolysis-Targeting Chimeras (PROTACs), offer a promising approach to address these shared pathways. PROTACs leverage the ubiquitin-proteasome system to specifically degrade pathogenic proteins involved in cancer and aging, thus offering potential solutions to key oncogenic drivers and aging-related cellular dysfunction. This abstract summarizes the recent progress of PROTACs in targeting critical proteins implicated in both cancer progression and aging, and explores future perspectives in integrating these technologies for more effective cancer treatments.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper discusses the use of PROTACs to target aging-related signaling pathways in cancer, which aligns with the broader goal of addressing root causes of aging and cellular dysfunction. However, while it presents a solid approach to a significant issue, the advancements described appear to be incremental rather than groundbreaking, limiting its overall impact on the field of longevity research.

Author of this paper? Send a correction.